8 completed, 8 recruiting, 6 active not recruiting, 3 terminated. 27 Phase 2, 12 Phase 1, 1 Phase 3.
Follow SCLC: new trials by email Literature Review of SCLC trials Research Report on SCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms Topotecan - usual, Topotecan - study - SCLC | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | 600 | 2026-10-05 | 2026-10-08 |
| Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC golidocitinib with PD-1 inhibitors - SCLC, SCLC, Extensive Stage | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 20 | 2025-10-31 | 2026-02-27 |
| 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer Sequential [18F]-FDG PET/CT, [68Ga]Ga-PFD3 PET/CT scan - SCLC, SCLC, Extensive Stage | Phase 1 / Phase 2 | Recruiting | Peking University First Hospital | 30 | 2025-10-22 | 2026-06-18 |
| Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study irinotecan liposome(II) plus Ivonescimab via intravenously (IV) Q3W for 4-6 cycles, followed by Ivonescimab until disease progression or intolerable toxicity - SCLC | Phase 2 | Not yet recruiting | The Second Affiliated Hospital of Dalian Medical University | 40 | 2025-02-28 | 2025-02-11 |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors TUB-030 - Advanced Solid Tumors, HNSCC | Phase 1 / Phase 2 | Recruiting | Gilead Sciences | 250 | 2024-12-13 | 2026-09-11 |
| Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study Mirabegron - NSCLC, SCLC | Phase 2 | Recruiting | Zhejiang Provincial People's Hospital | 260 | 2024-07-15 | 2024-08-02 |
| Adebrelimab + Apatinib in SCLC Maintenance Therapy Adebrelimab combined with Apatinib - SCLC | Phase 2 | Recruiting | Tang-Du Hospital | 60 | 2024-06-20 | 2024-06-26 |
| MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer Durvalumab, Monalizumab, Carboplatin or Cisplatin - Small Cell Lung Cancer, SCLC | Phase 2 | Recruiting | Khalil Choucair | 84 | 2023-09-26 | 2026-11-05 |
| A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC PM8002, Platinum, Etoposide - SCLC | Phase 2 | Active not recruiting | Biotheus Inc. | 50 | 2023-06-01 | 2025-03-12 |
| Study of Oral MRT-2359 in Selected Cancer Patients Oral MRT-2359 - NSCLC, SCLC | Phase 1 / Phase 2 | Active not recruiting | Monte Rosa Therapeutics, Inc | 174 | 2022-10-12 | 2026-11-06 |
| A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC PM8002, Paclitaxel - SCLC | Phase 2 | Active not recruiting | Biotheus Inc. | 99 | 2022-05-27 | 2024-12-18 |
| A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors Berzosertib, Sacituzumab Govitecan - HRD Cancer, SCLC | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 35 | 2021-09-20 | 2026-07-21 |
| Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer Nivatrotamab - SCLC | Phase 1 / Phase 2 | Terminated | Y-mAbs Therapeutics | 3 | 2021-08-17 | 2023-08-14 |
| Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers Lurbinectedin, Berzosertib - SCLC, Small Cell Cancer | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 37 | 2021-06-01 | 2026-03-17 |
| A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors JAB-8263 - NSCLC, SCLC | Phase 1 / Phase 2 | Recruiting | Jacobio Pharmaceuticals Co., Ltd. | 152 | 2021-05-07 | 2026-01-09 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
| Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer Anlotinib hydrochloride, Etoposide, Carboplatin - SCLC, Anlotinib | Phase 2 | Unknown | Shanghai Chest Hospital | 29 | 2019-05-01 | 2020-12-24 |
| Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] AZD6738, Olaparib - SCLC | Phase 2 | Completed | Samsung Medical Center | 26 | 2018-10-17 | 2021-02-18 |
| A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Nivolumab, Plinabulin, Ipilimumab - Lung Cancer, SCLC | Phase 1 / Phase 2 | Completed | Salma Sabbour | 39 | 2018-09-06 | 2026-01-20 |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Lurbinectedin, Irinotecan - Advanced Solid Tumors, Glioblastoma | Phase 1 / Phase 2 | Completed | PharmaMar | 316 | 2016-05-06 | 2025-07-09 |
Showing 20 of 27. Sign in to see all of them.
Small Cell Lung Carcinoma (10) · Lung Neoplasms (5) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Ovarian Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Carcinoma, Small Cell (2) · Endometrial Neoplasms (2) · Head and Neck Neoplasms (2) · Neoplasms (2) · Prostatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Stomach Neoplasms (2) · Carcinoma, Ovarian Epithelial (1)
Neoplasms by Site (15) · Neoplasms (13) · Lung Diseases (12) · Respiratory Tract Diseases (12) · Respiratory Tract Neoplasms (12) · Thoracic Neoplasms (12) · Bronchial Neoplasms (10) · Carcinoma, Bronchogenic (10) · Lung Neoplasms (7) · Neoplasms by Histologic Type (6) · Breast Diseases (5) · Carcinoma (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Genital Diseases (5)
Etoposide (3) · pazopanib (3) · Carboplatin (2) · Cisplatin (2) · PM 01183 (2) · berzosertib (2) · durvalumab (2) · olaparib (2) · Bevacizumab (1) · Drug Therapy (1) · E-3810 (1) · Immune Checkpoint Inhibitors (1) · Ipilimumab (1) · Irinotecan (1) · NPI 2358 (1)
Biotheus Inc. (2) · National Cancer Institute (NCI) (2) · Samsung Medical Center (2) · Astellas Pharma Inc (1) · AstraZeneca (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Clovis Oncology, Inc. (1) · Dana-Farber Cancer Institute (1) · Eli Lilly and Company (1) · Gilead Sciences (1) · Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair (1) · Hellenic Oncology Research Group (1) · Jacobio Pharmaceuticals Co., Ltd. (1) · Khalil Choucair (1) · Monte Rosa Therapeutics, Inc (1)
United States (14) · China (9) · France (5) · South Korea (4) · Spain (4) · Germany (3) · Italy (3) · United Kingdom (3) · Netherlands (2) · Switzerland (2) · Australia (1) · Belgium (1) · Canada (1) · Greece (1) · Israel (1)
Anish Thomas, M.D. (2) · Ying Cheng (2) · Baohui Han (1) · David Jackman, MD (1) · Khalil Choucair, MD, MSc (1) · Liu Yang, M.D. (1) · Marc Fellous, MD (1) · Salma Jabbour, MD (1) · Susan Domchek, MD (1) · Wei Zheng, MD (1) · Yariv Houvras, MD, PhD (1)
PMID 32771088, PMID 35756843, PMID 35844029, PMID 36116169, PMID 37491889, PMID 37939124, PMID 39173229, PMID 40543428, PMID 40932470, PMID 40963055, PMID 41740031, PMID 41791703, PMID 42081171
2015 (1)